NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors |
|
|
| Recruiting | 2 | 66 | Europe, US | Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan | Taiho Oncology, Inc. | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer | 01/25 | 05/25 | | |
NCT04018872: Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer |
|
|
| Recruiting | 2 | 78 | US | Itraconazole | Dallas VA Medical Center | Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma | 06/26 | 09/26 | | |
NCT05563766: A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer |
|
|
| Recruiting | 2 | 78 | US | Itraconazole | VA Office of Research and Development, Durham VA Health Care System, VA Palo Alto Health Care System, Portland VA Medical Center, VA Puget Sound Health Care System, Michael E. DeBakey VA Medical Center, VA Boston Healthcare System, North Texas Veterans Healthcare System, VA Ann Arbor Healthcare System | Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma | 04/29 | 06/29 | | |
